KorrekturOpen Access · CC BY-NC 3.0
Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]
Oncolytic Virotherapy · 2019
DOI: 10.2147/ov.s196145 ↗Kurz gefasst
Korrektur in der Zeitschrift Oncolytic Virotherapy, 2019. Verfasst von Hani M. Babiker und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona Cancer Center. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- University of Arizona Cancer Center
- Department of Internal Medicine, University of Arizona, Tucson
- Division of Hematology-Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ
- Department of Molecular Medicine, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA
Zitieren
APA
Babiker, H. M., Riaz, I. B., Husnain, M., & Borad, M. J. (2019). Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]. Oncolytic Virotherapy. https://doi.org/10.2147/ov.s196145
Vancouver
Babiker HM, Riaz IB, Husnain M, Borad MJ. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]. Oncolytic Virotherapy. 2019. doi:10.2147/ov.s196145
BibTeX
@article{Babiker2019,
author = {Babiker, Hani M. and Riaz, Irbaz Bin and Husnain, Muhammad and Borad, Mitesh J.},
title = {Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]},
journal = {Oncolytic Virotherapy},
year = {2019},
doi = {10.2147/ov.s196145}
}
EUVIMED